| Metabolex, Inc. is a privately held company, founded to discover and develop therapeutics for diabetes and related metabolic diseases. The company's lead compound is MBX-102, a novel insulin sensitizer in early stage human clinical testing. Metabolex's product pipeline includes preclinical compounds directed at insulin resistance, insulin secretion, and hepatic glucose output in type 2 diabetes. The company's drug target discovery programs have produced one of the world's largest databases of diabetes-expressed genes. Metabolex has collaborations with Abbott Laboratories and Pfizer. |
